Treatment of patients developing steroid-refractory acute GvHD (SR-aGVHD) after allogeneic hematopoietic cell transplantation (HCT) remains a major therapeutic challenge. Mesenchymal stromal cells (MSC) have been used in this setting for over a decade. While many factors have been reported to play a role in response rates to MSC, including cell dose, culture passages, culture media and time to intervention, the overall effectiveness and optimal positioning of MSC in the management of patients with SR-aGVHD remains a matter of discussion. [1] [2] [3] [4] [5] [6] Here we present a single center experience on early intervention with MSC in patients with SR-aGVHD leading to high overall and complete response (CR) rates associated with improved overall survival, which contributes to the body of evidence in this field.
Allogeneic HCT recipients with grade II-IV (Glucksberg modified criteria) SR-aGVHD were eligible for this study. Refractoriness to steroids was defined as: (1) progression after three days of treatment with 2 mg/kg methylprednisolone; (2) no response at day seven, or (3) no partial response at day 14. Patients were intended to receive a minimum of four MSC infusions given twice weekly. When CR was not achieved, additional weekly infusions were allowed. MSC production and administration was approved by the Institutional Ethics Committee and the National Regulatory Agency (EudraCT 2010-022316-39; 2005-005075). Third-party allogeneic clinical-grade MSC were isolated from bone marrow, cultured, expanded and cryopreserved in our Cell Production Unit following GMP standards, as previously described. 7 Patients were treated from 2006 to 2014. From 2011, fetal calf serum (FCS) was replaced with platelet lysate (PL), obtained from 5-10 donor pooled apheresis frozen at − 80°C and then thawed at 37°C. [8] [9] [10] Harvested MSC were required to comply with previously defined criteria:
11 spindle-shaped morphology and 490% cells expressing CD73, CD90, CD105, CD166 and HLA class I antigens and o 10% expressing CD31, CD34, CD45, CD80 and HLA class II antigens by immune-phenotype (FC-500, Beckman Coulter, Madrid, Spain). MSC units were administered immediately after thawing. The primary endpoint was response to treatment at day 28 after the first MSC infusion, classified as CR (resolution of all aGVHD symptoms in every organ affected), partial response (PR; reduction of manifestations of aGVHD in at least one overall grade according to Glucksberg modified criteria) and no response (NR; progressive disease, stable disease or minimal response which does not reach criteria for PR). Secondary endpoints included response to treatment at day 90, survival rates at days 28 and 90, cause of death and longer-term overall survival (OS) as a time-dependent variable. Absolute and relative frequencies were used to describe categorical variables, median, range and interquartile range (IQR) for continuous variables, and the Chi-square or Fisher exact tests for categorical variable group comparisons. The probability of OS was estimated by the Kaplan-Meier method and log-rank test. Stata/IC version 14 (StataCorp LP; College Station, TX, USA) was used for statistical analysis. Reported P-values are two-sided and were accepted as statistically significant if o 0.05.
This series includes 33 allogeneic HCT recipients, 22 men, median age 46 years old (range 18-61), from HLA-identical sibling donors (14; 42%), unrelated donors (10; 30%) or cord blood (9; 27%), who developed grade II-IV SR-aGVHD ( Table 1) . The onset of aGVHD occurred at a median day +77 after HCT (IQR, 33.5-146). Target organ involvement included the skin in 22 cases (66.7%), gastrointestinal tract (GI) in 26 (78.7%) and liver in 7 (21.2%); 17 patients had grade II (52%), nine grade III (27%) and seven grade IV (21%) SR-aGVHD. First-line treatment of aGVHD included 2 mg/kg methylprednisolone plus calcineurin inhibitors. Patients started MSC therapy at a median of 10 days after the onset of aGVHD (IQR, 4-24), and received a median of four MSC infusions (range 1-16). Third-party MSC were produced with FCS in 15 cases, with PL in 13 cases, and five cases received doses of MSC produced with both FCS and PL. The median MSC dose infused per unit was 1.06 × 10 6 /kg (range 0.66 to 1.76). MSC infusions were well tolerated with no relevant adverse events. Upon initiation of MSC therapy, calcineurin inhibitors were maintained and steroid-dose tapered progressively until suspension. Patients not responding to MSC received additional therapy with anti-TNF, alemtuzumab or pentostatin, based on the treating physician's decision (data not shown).
Response to MSC therapy was evaluable in 32 of the 33 patients (Table 2) . By day 28 after the first MSC dose, 11 patients achieved CR (34%), 16 PR (50%) and 5 NR (16%). The median time to response from the first dose of MSC was 14 days (interquartile range (IQR): 10-28). Two subjects died by day 28 (6%), one with NR from SR-aGVHD progression and one with PR from pulmonary infection. Response at day 28 associated with response at day 90 (P = 0.001), so that 10 patients with CR and six with PR on day 28 were in CR by day 90 (16, 50%), while the others remained on PR or lost response (8, 25% each PR and NR). Patients achieving CR by day 28 after MSC therapy had higher survival rates at day 90 (100% vs 47.6%; P = 0.006) and improved longer term OS (79% vs 25% at 1 year and median OS 43.2 vs 3.4 months, respectively; P = 0.002) compared with patients with PR/NR. Causes of death at day 90 from MSC treatment, all occurring in the PR/NR cohort, were infections (7), progressive SR-aGVHD (2) and hemorrhage (1). For patients with grades II, III and IV SR-aGVHD, CR rates at day 28 were 53, 25 and 0% respectively (P = 0.037), with no translation into differences in survival. Also, patients with GI involvement had poorer CR rates (20 vs 86%; P = 0.003) without a significant impact on survival. Importantly, response to treatment and survival were not associated with the use of FCS versus PL for MSC production. Also, response and survival after MSC did not appear to be influenced by other factors related to the patient (age, gender, underlying disease or remission status at HCT), the transplant (donor type, age or gender, intensity of conditioning or GVHD prophylaxis) or other MSC characteristics (number of passages; all statistically not significant, data not shown). Six patients in CR at day 90 had a later progression of their GVHD at a median of 154 days. Only one patient in the series suffered a relapse of his underlying malignancy (acute myeloid leukemia) three years after MSC therapy, while in CR of his GVHD and with no immunosuppressive therapy.
Mesenchymal stromal cells are a recognized therapeutic option for patients with SR-aGVHD. [1] [2] [3] [4] [5] [6] Our data add to this body of evidence and suggest that their use early in the treatment, at a median of 10 days from aGVHD onset, leads to encouraging CR rates of 34 and 50% and overall response rates of 84 and 75% at day 28 and 90, respectively. As in other studies, 12 our data identified the severity of aGVHD as a predictor of clinical response. Patients achieving CR after MSC therapy had a prolonged median overall survival of over 3.5 years. Our study suggests that patients with GI involvement may have a poorer response to MSC therapy than those without it. Some groups have reported better responses to MSC in cutaneous and GI than hepatic aGvHD, 5, 6 and others found no differences in outcome or response rate among target organs. 1, 13 Early intervention with MSC after aGVHD onset has been regarded as an important factor for a better patient outcome in some series, but not all. 5, 6 We found high overall and CR rates with an early intervention with MSC from aGVHD onset, which contributes to this evidence, but our homogeneous and relatively small series does not allow for a formal analysis of the impact of time to intervention on outcome. Since 2009, several groups have shown that FCS can be safely replaced with PL to avoid the use of animal derived products in MSC production. 4, 8, 9 However, few studies have been published with this change in supplement media and hardly any examine its potential impact on response rate. Our study suggests that the replacement of FCS with PL not only increases product safety but it preserves MSC efficacy and patients' response rates.
The first large multicentric study of BM-derived MSC for SRaGVHD, reported by the EBMT MSC Consortium, showed a 55% CR, 16% PR and 71% overall response rates, 1 in line with our findings. The only important randomized controlled trial in this area (Prochymal, Osiris Therapeutics) showed response rates after MSC comparable to placebo of only 35 and 40% in the intention to treat and per protocol populations, respectively. The study, however, remains only available in abstract form. 2 Our data contribute to the role of allogeneic third-party MSC as a safe and effective therapeutic option for patients with SR-aGVHD. We found no MSC infusion related early adverse events. In addition to their safety, early intervention in SR-aGVHD patients with MSC may lead to an overall response in 75% of patients, CR in 50%, which associate with an improved overall survival at day 90 after start of MSC treatment. Our findings and those from other recent studies offer new insights on the use of MSC in this clinical setting. 14, 15 However, well-designed prospective randomized studies with MSC are warranted to assess their efficacy and to consolidate the role of this therapeutic strategy in patients with SR-aGVHD. Abbreviations: ATG = thymoglobulin; CR = complete response; HCT = hematopoietic cell transplantation; MAC = myeloablative conditioning; MDS = myelodysplastic syndrome; MM = multiple myeloma; MSC = mesenchymal stromal cells; RIC = reduced intensity conditioning; TCD = T-cell depletion. a 1 severe aplastic anemia, 1 myeloproliferative disorder other than CML and 1 GATA2 deficiency. 
